机译:核碱基和核糖修饰通过MicroRNA-122模拟RNA控制免疫刺激。
Department of Chemistry, University of California—Davis, One Shields Avenue, Davis, California 95616, United States;
Sirna Therapeutics, a wholly owned subsidiary of Merck and Co., 1700 Owens Street, fourth Floor, San Francisco, California 94158,United States;
Department of Chemistry, University of California—Davis, One Shields Avenue, Davis, California 95616, United States;
Department of Chemistry, University of California—Davis, One Shields Avenue, Davis, California 95616, United States;
Sirna Therapeutics, a wholly owned subsidiary of Merck and Co., 1700 Owens Street, fourth Floor, San Francisco, California 94158,United States;
Sirna Therapeutics, a wholly owned subsidiary of Merck and Co., 1700 Owens Street, fourth Floor, San Francisco, California 94158,United States;
Sirna Therapeutics, a wholly owned subsidiary of Merck and Co., 1700 Owens Street, fourth Floor, San Francisco, California 94158,United States;
Department of Chemistry, University of California—Davis, One Shields Avenue, Davis, California 95616, United States;
机译:中性环状ADP-核糖模拟的钙调动能力,其对核碱基,北核糖和焦磷酸酯的改性
机译:通过核碱基修饰控制siRNA的miRNA样脱靶效应
机译:整合了碱基,北部和南部核糖修饰的cADPR类似物的合成和钙动员活性
机译:在印迹基因的发育控制中非致rnas和染色质修饰
机译:用鸟嘌呤核酸酶修饰改善siRNA特异性:TLR8响应和miRNA样的偏离目标效果
机译:Nucleobase和核糖修饰通过MicroRNA-122 - 模拟RNA控制免疫刺激
机译:整合核碱基,北部和南部核糖修饰的caDpR类似物的合成和钙动员活性